Sanofi (Sanofi) Long-Term Capital Lease Obligation : $1,992 Mil (As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi Long-Term Capital Lease Obligation?

Sanofi's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was $1,992 Mil.

Sanofi's quarterly Long-Term Capital Lease Obligation declined from Jun. 2022 ($2,115 Mil) to Dec. 2022 ($2,017 Mil) and declined from Dec. 2022 ($2,017 Mil) to Jun. 2023 ($1,992 Mil).

Sanofi's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($2,078 Mil) to Dec. 2022 ($2,017 Mil) and declined from Dec. 2022 ($2,017 Mil) to Dec. 2023 ($1,914 Mil).

Sanofi Long-Term Capital Lease Obligation Historical Data

The historical data trend for Sanofi's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Long-Term Capital Lease Obligation Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1,096.67

2,237.23

2,077.97

2,016.95

1,913.85

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															2,077.97	2,115.22	2,016.95	1,992.42	1,913.85

Sanofi (NAS:SNY) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Sanofi Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sanofi's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.